The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Treatment of bulky stage I/II lymphoma
David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, outlines the treatment of bulky stage I/II lymphoma, including strategies to reduce the risk of side effects of combined modality treatments involving radiotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
